Venetoclax has a high affinity for the BH3 binding domain of BCL-2 and promotes apoptosis as well as inhibits cell proliferation by suppressing high BCL-2 expression in AML cells [40, 41]. The gene discussed is BCL2; the disease is acute myeloid leukemia.